Mantle Cell Lymphoma
Conference Coverage
MCL treatment choices depend partly on age
CHICAGO – There are important treatment differences in patients aged 65 and younger versus those over 65.
Conference Coverage
Prognostic factors guide mantle cell treatment decisions
CHICAGO –
From the Journals
Outpatient lenalidomide/rituximab yields long-term MCL remission
Nearly two-thirds of evaluable patients with mantle cell lymphoma had durable responses to induction and maintenance.
Latest News
New mantle cell trials launching
At least four new mantle cell lymphoma trials were registered in Clinicaltrials.gov in August 2018.
From the Journals
TP53 mutation plus complex karyotype equals poor prognosis
The two markers signaled worse overall survival among mantle cell lymphoma patients.
From the Journals
Adverse events outweigh promise of SGN-CD70A against NHL
Despite a handful of durable remissions of non-Hodgkin lymphomas with the antibody-drug conjugate, thrombocytopenias canceled out the benefit.
Feature
New BTK inhibitor under review in China
Zanubrutinib is being reviewed for treatment of relapsed/refractory mantle cell lymphoma.
From the Journals
Meta-analysis supports rituximab maintenance in MCL
Rituximab maintenance therapy prolonged progression-free survival. Risk of grade 3 or 4 neutropenia was increased, but risk of infection was not...
From the Journals
PET/CT accurately predicts MCL stage
The promising results suggest bone marrow involvement could be assessed without a biopsy.
From the Journals
Late mortality risk after childhood BMT is substantial, persistent
Patients who undergo blood or marrow transplant as children need “lifelong follow-up care.”
From the Journals
New guideline for managing MCL